Scandinavian ChemoTech receives new approval in Japan for its TSE for deep seated tumours
Scandinavian ChemoTech has received the final approval for its DEEPC patent application in Japan. The patent protects the innovation used for the TSE therapy in deep seated tumours and secondary bone cancer.The approval is considered by ChemoTech to be of significant importance for future negations with potential industrial partners as Japan is an important market for the Company´s clinical project regarding deep seated tumours. "Obtaining this approval for this innovation in Japan is very important for the continued protection of our TSE platform and makes it more interesting for